AstraZeneca Vaccine Blood Clot Issue: Company Acknowledges

AstraZeneca Vaccine Blood Clot Issue: Company Acknowledges

AstraZeneca Vaccine Blood Clot


AstraZeneca Vaccine Potential Blood Clotting Issues

According to a report published in Dawn newspaper, the well-known pharmaceutical company's COVID vaccine, AstraZeneca, may be linked to blood clotting (thrombosis) and low platelet counts.


Company's Admission and Legal Challenges

The pharmaceutical company is facing a lawsuit where a group of people alleges that its vaccine, developed in collaboration with Oxford University, has caused deaths and serious injuries in several instances.


The company has admitted in court documents that the AstraZeneca vaccine may be responsible for causing a rare condition known as TTS (thrombosis with thrombocytopenia syndrome), but the exact reason for this interesting condition isn't yet known.


Background of AstraZeneca Vaccine

The vaccine, known as Covishield, was developed through a collaboration between a British-Swedish company and Oxford University. It was manufactured by the Serum Institute of India and has been widely used in more than 150 countries worldwide.


Efficacy and Controversy

Studies conducted during the pandemic have shown that this vaccine is 60 to 80 percent effective in protecting against the novel coronavirus.


However, one of the complainants alleged that the use of the vaccine resulted in bleeding in their brain, leading to a future risk of cerebral injury.


Scientific Findings

Scientists initially identified a link between the vaccine and the rare condition in March 2021, which they termed as Vaccine-induced Thrombotic Thrombocytopenia (VITT).


After incidents of blood clotting following the use of AstraZeneca in March 2021, Denmark, Norway, Iceland, and Italy temporarily suspended the use of the vaccine.